Fate Therapeutics, Inc. FATE
1.64 USD -0.13 (-7.56%)
Nov 11, 2026, 2:43 PM EST
1.63 Day range 1.78
0.95 52-week range 3.23
- YTD
- +66.95%
- 1 year
- +46.08%
News
globenewswire.com Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of…
benzinga.com Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $3 Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $3.5 to $3.
benzinga.com Fate Therapeutics Q3 EPS $(0.25) Beats $(0.27) Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 7.41 percent increase over losses of…
globenewswire.com Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further…
benzinga.com Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.- benzinga.com Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026 Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
- benzinga.com Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive…
benzinga.com Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026 Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
benzinga.com Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
benzinga.com Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8 Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.- benzinga.com Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5 Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
- benzinga.com Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
- benzinga.com Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated…
- benzinga.com Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of…
benzinga.com Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales guidance. Other stocks also down in pre-market.
benzinga.com CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026 Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…- benzinga.com Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.
- benzinga.com Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
- benzinga.com Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
- benzinga.com Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of…
- benzinga.com Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session - benzinga.com Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
- benzinga.com Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15 Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to…
- benzinga.com HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7 HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.
- benzinga.com Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
- benzinga.com Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
benzinga.com Fate Therapeutics Q4 Earnings Summary & Key Takeaways 
benzinga.com Earnings Summary: Fate Therapeutics Q4 - benzinga.com Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 38.64 percent increase over losses of…
benzinga.com Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient…
benzinga.com Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of…
benzinga.com HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5 HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.- benzinga.com Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $7 Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price target from $5 to $7.
- benzinga.com Reported Sunday, Fate Therapeutics Presents FT819 Phase 1 Data Demonstrating Immune Remodeling And Durable Responses In 10 Patients With Systemic Lupus Erythematosus As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $2.5 Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $4 to $2.5.
- benzinga.com Fate Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $1.907M Beat $1.011M Estimate Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 12.12 percent increase over losses of…
- benzinga.com Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
- benzinga.com Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
- benzinga.com Earnings Scheduled For February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.